Neurocrine Biosciences (NBIX) officer exercises options, sells 4,367 shares

Rhea-AI Filing Summary

Neurocrine Biosciences Inc. Chief Regulatory Officer Ingrid Delaet reported an exercise-and-sale sequence in company stock. She exercised options to acquire 4,367 shares of common stock at $106.02 per share and, on the same date, sold 4,367 shares in open-market transactions at an average price of $181.02 per share. Following these transactions, she held 20,592 shares of common stock directly in one non-derivative holding and 16,225 shares in another reported line. The sale was carried out by a broker under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2026, and the exercised options were originally granted in 2021 with a vesting schedule through 2025.

Filing Explained

The officer exercised 4,367 options and sold the same number, leaving 16,225 direct shares reported after the July 10 transactions.

The July 13, 2026 Form 4 reports that Neurocrine Biosciences’ Chief Regulatory Officer exercised an option and sold shares on July 10, 2026.

The exercise and sale each involved 4,367 common shares, leaving 16,225 shares held directly after the reported transactions.

Form 4 coding identifies M as an option or derivative exercise and S as an open-market sale; the option exercise was reported at $106.02 per share and the sale at $181.02 per share.

The filing states that the sale was executed by a broker under a Rule 10b5-1 plan adopted on February 27, 2026; such a plan is a written trading plan adopted in advance that executes trades on a schedule or formula.

The filing does not disclose an issuer-level structural change or a directional consequence for Neurocrine’s other common holders.

Insider Trade Summary 10b5-1

Net Seller: 4,367 shares ($790,514)

Net Sell 3 txns

Insider Delaet Ingrid

Role Chief Regulatory Officer

Sold 4,367 shs ($791K)

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option	4,367	$0.00	--
Exercise	Common Stock	4,367	$106.02	$463K
Sale	Common Stock	4,367	$181.02	$791K

Holdings After Transaction: Non-Qualified Stock Option — 0 shares (Direct); Common Stock — 20,592 shares (Direct)

Footnotes (1)

1. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Option granted February 1, 2021 and vested at 25% upon first anniversary (February 1, 2022) and remaining 75% vested in 36 equal monthly installments beginning on March 1, 2022.

Key Figures

Shares sold: 4,367 shares Sale price: $181.02 per share Option exercise price: $106.02 per share +5 more

8 metrics

Shares sold 4,367 shares Common stock sold in open-market transactions on July 10, 2026

Sale price $181.02 per share Average price for 4,367 common shares sold

Option exercise price $106.02 per share Exercise price for 4,367 shares underlying non-qualified stock options

Shares acquired via exercise 4,367 shares Common stock acquired through option exercise on July 10, 2026

Direct holdings (one line) 20,592 shares Total common shares shown following one non-derivative transaction

Direct holdings (second line) 16,225 shares Total common shares shown following the reported sale transaction

Option expiration date February 1, 2031 Expiration for the non-qualified stock option that was exercised

10b5-1 plan adoption February 27, 2026 Date the Rule 10b5-1 trading plan governing the sale was adopted

Key Terms

Rule 10b5-1 trading plan, Non-Qualified Stock Option, Exercise or conversion of derivative security, vesting

4 terms

Rule 10b5-1 trading plan regulatory

"The disposition was effected by a broker pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Non-Qualified Stock Option financial

"Security title listed as Non-Qualified Stock Option with underlying common stock"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

Exercise or conversion of derivative security financial

"Transaction code M described as Exercise or conversion of derivative security"

vesting financial

"Option granted February 1, 2021 and vested at 25% upon first anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/13/2026 - 04:28 PM Accepted by SEC EDGAR 07/13/2026 - 04:27 PM Learn about SEC filing dates

FAQ

What insider stock transactions did NBIX executive Ingrid Delaet report?

Ingrid Delaet, Chief Regulatory Officer of NBIX, reported exercising options for 4,367 shares at $106.02 and selling 4,367 shares of common stock at an average price of $181.02 per share on the same date, as part of a planned transaction.

How many Neurocrine Biosciences (NBIX) shares does Ingrid Delaet hold after the Form 4 transactions?

After the reported transactions, Ingrid Delaet is shown holding 20,592 shares of NBIX common stock in one line of non-derivative holdings and 16,225 shares in another, both reported as directly owned, reflecting her remaining equity position following the exercise-and-sale activity.

At what prices did Ingrid Delaet exercise and sell NBIX shares?

She exercised stock options to acquire 4,367 NBIX shares at an exercise price of $106.02 per share, then sold 4,367 shares of common stock in the open market at an average price of $181.02 per share, according to the reported Form 4 transactions.

Were Ingrid Delaet’s NBIX stock sales under a Rule 10b5-1 trading plan?

Yes. The footnotes state the disposition was effected by a broker pursuant to a Rule 10b5-1 trading plan adopted by Ingrid Delaet on February 27, 2026. Company policy restricts her from amending or modifying the plan after adoption, indicating the sales were pre-arranged.

What were the terms of the NBIX stock options exercised by Ingrid Delaet?

The exercised non-qualified stock options for 4,367 underlying NBIX shares had an exercise price of $106.02 and an expiration date of February 1, 2031. They were granted on February 1, 2021, vesting 25% after one year and the remaining 75% in 36 monthly installments.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Delaet Ingrid

(Last) (First) (Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Regulatory Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/10/2026		M		4,367	A	$106.02	20,592	D
Common Stock	07/10/2026		S(1)		4,367	D	$181.02	16,225	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option	$106.02	07/10/2026		M			4,367	(2)	02/01/2031	Common Stock	4,367	$0	0	D

Explanation of Responses:

1. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

2. Option granted February 1, 2021 and vested at 25% upon first anniversary (February 1, 2022) and remaining 75% vested in 36 equal monthly installments beginning on March 1, 2022.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	07/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)